Impact of nationwide enhanced implementation of best practices in pancreatic cancer care (PACAP-1): a multicenter stepped-wedge cluster randomized controlled trial

Autor: T. M. Mackay, F. J. Smits, A. E. J. Latenstein, A. Bogte, B. A. Bonsing, H. Bos, K. Bosscha, L. A. A. Brosens, L. Hol, O. R. C. Busch, G. J. Creemers, W. L. Curvers, M. den Dulk, S. van Dieren, L. M. J. W. van Driel, S. Festen, E. J. M. van Geenen, L. G. van der Geest, D. J. A. de Groot, J. W. B. de Groot, N. Haj Mohammad, B. C. M. Haberkorn, J. T. Haver, E. van der Harst, G. J. M. Hemmink, I. H. de Hingh, C. Hoge, M. Y. V. Homs, N. C. van Huijgevoort, M. A. J. M. Jacobs, E. D. Kerver, M. S. L. Liem, M. Los, H. Lubbinge, S. A. C. Luelmo, V. E. de Meijer, L. Mekenkamp, I. Q. Molenaar, M. G. H. van Oijen, G. A. Patijn, R. Quispel, L. B. van Rijssen, T. E. H. Römkens, H. C. van Santvoort, J. M. J. Schreinemakers, H. Schut, T. Seerden, M. W. J. Stommel, A. J. ten Tije, N. G. Venneman, R. C. Verdonk, J. Verheij, F. G. I. van Vilsteren, J. de Vos-Geelen, A. Vulink, C. Wientjes, F. Wit, F. J. Wessels, B. Zonderhuis, C. H. van Werkhoven, J. E. van Hooft, C. H. J. van Eijck, J. W. Wilmink, H. W. M. van Laarhoven, M. G. Besselink, for the Dutch Pancreatic Cancer Group

Publikováno v: Trials, Vol 21, Iss 1, Pp 1-18 (2020)

Abstract Background Pancreatic cancer has a very poor prognosis. Best practices for the use of chemotherapy, enzyme replacement therapy, and biliary drainage have been identified but their implementation in daily clinical practice is often suboptimal

Externí odkaz: https://doaj.org/article/778d6790076f4b19a04ca4000032fef5

Supplementary Data from Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry

Autor: Karijn P.M. Suijkerbuijk, Ellen Kapiteijn, John B.A.G. Haanen, Michel W.J.M. Wouters, Michiel C.T. van Zeijl, Gerard Vreugdenhil, Astrid A.M. van der Veldt, Albert J. ten Tije, Rozemarijn S. van Rijn, Djura Piersma, Geke A. Hospers, Jacobus J.M. van der Hoeven, Marye J. Boers-Sonderen, Jan Willem B. de Groot, Alfonsus J.M. van den Eertwegh, Franchette W.P.J. van den Berkmortel, Maureen J.B. Aarts, Christian U. Blank, Anne M. May, Rik J. Verheijden

Suppl. tab. S1 | Multivariable Cox regression of baseline factors associated with overall survival in all first-line checkpoint inhibitor treated patients Suppl. tab. S2 | Multivariable Cox regression of baseline factors associated with overall survi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::742a384f917f9cb609af63491e5128a5
https://doi.org/10.1158/1078-0432.22477943.v1

Supplementary Table 2 from Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study

Autor: Ron H.J. Mathijssen, Ronald de Wit, Dana Chitu, Nelly van der Meer, Hanneke Zuetenhorst, Albert J. ten Tije, Henk van Halteren, Aart Beeker, Andries M. Bergman, Robbert J. van Alphen, Robert J. van Soest, Sander Bins, Paul Hamberg, Anne-Joy M. de Graan, Annemieke J.M. Nieuweboer

Reasons of inevaluability

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f44a456a75d980de02959594fee7a8d
https://doi.org/10.1158/1078-0432.22464081.v1

Data from Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study

Autor: Ron H.J. Mathijssen, Ronald de Wit, Dana Chitu, Nelly van der Meer, Hanneke Zuetenhorst, Albert J. ten Tije, Henk van Halteren, Aart Beeker, Andries M. Bergman, Robbert J. van Alphen, Robert J. van Soest, Sander Bins, Paul Hamberg, Anne-Joy M. de Graan, Annemieke J.M. Nieuweboer

Purpose: Forty-seven percent of patients in the pivotal trial of cabazitaxel reported diarrhea of any grade. Aiming to reduce the incidence of diarrhea, we studied the effects of budesonide on the grade of cabazitaxel-induced diarrhea during the firs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::135b34e783102f66d0d037c5cae20e33
https://doi.org/10.1158/1078-0432.c.6525612

Discontinuation of anti-PD-1 monotherapy in advanced melanoma

Autor: John B. A. G. Haanen, Maureen J.B. Aarts, Michel W.J.M. Wouters, Albert J. ten Tije, Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Rozemarijn S. van Rijn, Alfons J.M. van den Eertwegh, Liesbeth C. de Wreede, Ellen Kapiteijn, Geke A. P. Hospers, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, Gerard Vreugdenhil, Michiel C T van Zeijl, Jan-Willem B de Groot, Djura Piersma

Publikováno v: International Journal of Cancer, 150(2), 317-326. Wiley-Liss Inc.
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800

Contains fulltext : 287666.pdf (Publisher’s version ) (Open Access) There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti-PD-1 discontinuation,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4aecc11f2696429a42f3b7afc5d49f75
https://hdl.handle.net/11370/0e72933b-593e-414f-b5ab-c29ab695a795